RDNT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
RDNT is not a strong buy right now for a beginner long-term investor. The pre-market move is mildly positive, and hedge funds have been buying, but the chart is still structurally bearish on the moving averages and there is no fresh news or strong proprietary buy signal to support an immediate entry. Given the mixed setup and the user's impatience, I would not call this a good buy today; hold off unless the trend improves or a clearer breakout develops.
RDNT is showing short-term momentum improvement but the broader trend is not yet constructive. MACD histogram is positive and expanding, which supports near-term upside pressure, and RSI_6 at 59 is neutral to slightly bullish. However, the moving averages remain bearish with SMA_200 > SMA_20 > SMA_5, indicating the stock is still below a clean long-term uptrend. Pre-market price is 55.79, slightly above pivot 53.832 and just above R1 55.532, so it is testing resistance rather than breaking out decisively. A move through 56.582 would improve the setup, but at current levels the technical picture is only mixed.
Hedge funds are buying strongly, with buying amount up 139.49% over the last quarter. Analysts remain positive overall, with both Barclays and B. Riley keeping constructive ratings. Barclays highlighted outperforming advanced volume growth and imaging segment pricing, while B. Riley cited multi-indication PET volume growth. Options data is also bullish, and the stock is trading above the pivot in pre-market.
There has been no news in the recent week, so there is no fresh catalyst driving the move. The technical trend is still bearish on moving averages, which limits confidence in a long-term entry. Analyst price targets were reduced by both Barclays and B. Riley, showing some moderation in expectations. No recent AI Stock Picker or SwingMax signal is present, and no congress trading activity was reported.
No quarterly financial snapshot was available in the data, so latest-quarter revenue or earnings growth cannot be confirmed here. Because the missing financial data prevents a full fundamentals check, the decision relies more heavily on technicals, sentiment, and analyst/flow signals. The latest quarter season was not provided.
Wall Street remains constructive but slightly more cautious on price targets. On 2026-05-20 Barclays lowered its target to $65 from $70 while keeping Overweight, citing better advanced volume growth and imaging pricing versus Lumexa. On 2026-05-01 B. Riley cut its target to $83 from $87 but kept Buy, pointing to PET volume growth across Q1 reports. Overall, analysts still like the stock operationally, but target cuts show reduced upside expectations. Pros: continued Buy/Overweight ratings and favorable volume-growth commentary. Cons: price target reductions suggest less near-term valuation room than before.
